Inhibitory effects of Qushuanling Capsule (祛栓灵胶囊) on thrombus formation and platelet aggregation in rats
Tóm tắt
To investigate the effects of Qushuanling Capsule (祛栓灵胶囊 QSLC) on thrombus formation and platelet aggregation in rats. Arteriovenous bypass, venous thrombosis, and middle cerebral artery thrombosis models were used in rats to investigate the anti-thrombotic effects of QSLC, a compound of nine Chinese herbs. The platelet aggregation induced by adenosine diphosphate (ADP), thrombin or arachidonic acid (AA), as well as the contents of thromboxane B2 (TXB2) and 6-keto-prostaglandin F1α (6-keto-PGF1α) in rat plasma and aortic walls, were determined to investigate the possible mechanisms of the anti-thrombotic effects of QSLC. After oral administration with QSLC for 7 days, arteriovenous bypass thrombosis was obviously suppressed compared with the model group, venous thrombosis was also obviously suppressed, rat behaviors were obviously improved, and brain infarct size as well as water content were also reduced. The platelet aggregation induced by ADP or thrombin was inhibited by QSLC, but the drug had no effect on AA-induced platelet aggregation and content of TXB2 and 6-keto-PGF1α in plasma and the aortic wall. These results suggest that QSLC can be used in the prevention and treatment of thrombotic diseases, and that its mechanism of action may be related to inhibition of platelet aggregation.
Tài liệu tham khảo
Martín-Ventura JL, Blanco-Colio LM, Tuñón J, Muñoz-García B, Madrigal-Matute J, Moreno JA, et al. Biomarkers in cardiovascular medicine. Rev Esp Cardiol 2009;62:677–688.
Geerts WH, Berquist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest 2008;133(6 Suppl):381S–453S.
Green D. Risk of future arterial cardiovascular events in patients with idiopathic venous thromboembolism. Hematology 2009;1:259–266.
Adams JD, Wang R, Yang J, Lien EJ. Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions. Chin Med 2006;1:3–17.
Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, ‘mixed’ and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994;113:1209–1214.
Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986;17:472–476.
Gu ZL, Xie ML, Qian ZN. Ef fect of quercet in on chemiluminescence of human platelets induced by arachidonic acid. Acta Pharmacol Sin 1993;14:263–265.
Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983–989.
Fuster V, Chesebro JH. Mechanisms of unstable angina. N Engl J Med 1986;315:1023–1025.
Willerson JT, Hillis LD, Winniford M, Buja LM. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes. J Am Coll Cardiol 1986;8:245–250.
Wang GY, Gao YM, Hao YJ, Feng LQ. Study on pharmacological effects of Ginkgo biloba extract. Hubei J Tradit Chin Med (Chin) 2009;31:944–946.